4 Best Stocks to Buy According to Billionaire James Dinan

3. Humacyte, Inc. (NASDAQ:HUMA)

York Capital Management’s Stake Value: $7,355,000

Percentage of York Capital Management’s 13F Portfolio: 2.39%        

Number of Hedge Fund Holders: 9

Biotech firm Humacyte, Inc. (NASDAQ:HUMA) became a public company last year by merging with Alpha Healthcare Acquisition Corp., a SPAC, in a deal that valued the former at $1.1 billion. However, since becoming public Humacyte, Inc.’s (NASDAQ:HUMA) stock has been on a consistent downward path and has lost over 70% of its value in the last one year alone. Based in Durham, North Carolina, the company develops and manufactures implantable, off-the-shelf, and bioengineered human tissues for the treatment of diseases and conditions.

Analysts on Wall Street who track the stock have drastically divergent views on its trajectory. For example, BTIG Research’s analysts, who earlier had a price target of $12 on the stock, reduced it to $10 on July 15, which still represents a potential upside of over 150% from the stock’s current trading price. In comparison, analysts at Piper Sandler, who already had a low $4 price target on Humacyte, Inc.’s (NASDAQ:HUMA) stock, reduced it further to $3.5 on August 12, representing a potential downside of 11.4%.